Skip to main content

Table 1 Demographics, Aβ and neuropsychological test scores for each participant group

From: Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease

  HC
(n = 31)
MCI
(n = 12)
AD
(n = 13)
Group effect
Age, years
(range)
75.7 ± 5.6
(65–87)
77.4 ± 9.3
(63–93)
78.6 ± 7.8
(64–91)
F(2,53) = 0.85; p = 0.43
Sex (% women) 71% 33% 31% x2 = 8.47; p = 0.007
Education, years
(range)
15.8 ± 2.4
(8–20)
17.7 ± 2.0
(14–20)
16.0 ± 2.6
(12–20)
F(2,53) = 2.85; p = 0.07
DRS 139.8 ± 1.2 131.7 ± 2.0a 120.7 ± 1.9b,c F(2,50) = 34.22; p < 0.001
FAQ 0.8 ± 0.8 3.0 ± 1.4 14.6 ± 1.1b,c F(2,45) = 49.19; p < 0.001
LMI 15.6 ± 1.0 8.7 ± 1.5b 5.4 ± 1.4b F(2,49) = 18.31; p < 0.001
LMD 14.2 ± 1.1 5.2 ± 1.7b 1.9 ± 1.6b F(2,49) = 22.20; p < 0.001
CVLT-SFR 10.4 ± 0.5 2.9 ± 0.8b 1.9 ± 0.8b F(2,45) = 43.36; p < 0.001
CVLT-LFR 11.1 ± 0.4 3.2 ± 0.7b 1.5 ± 0.7b F(2,45) = 78.42; p < 0.001
CERAD-DR 7.2 ± 0.4 2.8 ± 0.6b 1.0 ± 0.6b F(2,48) = 38.82; p < 0.001
ANART-VIQ 118.3 ± 1.4 117.4 ± 2.2 115.1 ± 2.0 F(2,46) = 0.85; p = 0.43
  n = 24 n = 7 n = 7  
Aβ40, ng/ml 15.8 ± 1.2 11.5 ± 2.5 16.1 ± 2.3 F(2,32) = 1.21; p = 0.31
Aβ42, ng/ml 3.0 ± 0.2 1.5 ± 0.5 2.0 ± 0.4 F(2,32) = 4.58; p = 0.02
  1. Aβ and test scores are corrected for age, sex and education
  2. Values are shown as mean ± standard error unless otherwise noted
  3. a p < 0.01, compared to HC; b p < 0.001, compared to HC; c p < 0.001, compared to MCI, with Bonferroni correction for multiple comparisons
  4. amyloid-β, AD Alzheimer’s disease, ANART-VIQ, American National Reading Test Verbal IQ, CERAD-DR Consortium to Establish a Registry for Alzheimer’s Disease delayed recall, CVLT-LFR California Verbal Learning Test long delay free recall, CVLT-SFR California Verbal Learning Test short delay free recall, DRS Dementia Rating Scale, FAQ Functional Assessment Questionnaire, HC healthy controls, LMI Logical Memory immediate, LMD Logical Memory delayed, MCI mild cognitive impairment